# Blinded Safety & Efficacy Placebo Controlled Study of Icatibant for Angiotensin Converting Enzyme Inhibitor Induced Angioedema

> **NCT01919801** · PHASE3 · COMPLETED · sponsor: **Shire** · enrollment: 118 (actual)

## Conditions studied

- Angiotensin Converting Enzyme Inhibitor Induced Angioedema

## Interventions

- **DRUG:** Icatibant
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01919801
- **Lead sponsor:** Shire
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-12-02
- **Primary completion:** 2015-08-22
- **Final completion:** 2015-08-22
- **Target enrollment:** 118 (ACTUAL)
- **Last updated:** 2021-06-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01919801

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01919801, "Blinded Safety & Efficacy Placebo Controlled Study of Icatibant for Angiotensin Converting Enzyme Inhibitor Induced Angioedema". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01919801. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*